grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin-methicillin-resistant staphylococcus aureus

European Journal of Medical Research

Volumn 13, Issue 8, 2008, Pages 366-370

  Coskun Ari, Fatma Filiz ^a   Bosgelmez Tinaz, G ^a  

^a SULEYMAN DEMIREL UNIVERSITY   (Turkey)

Author keywords

Antimicrobial susceptibility; Gatifloxacin; grlA and gyrA mutations; MRSA

Indexed keywords

CEFOXITIN; CIPROFLOXACIN; COAGULASE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE IV; GATIFLOXACIN; LEUCINE; LINEZOLID; METICILLIN; OXAZOLIDINEDIONE DERIVATIVE; PENICILLIN BINDING PROTEIN 2A; PHENYLALANINE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE; TEICOPLANIN; TYROSINE; VANCOMYCIN;

AMINO ACID SUBSTITUTION; ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DISK DIFFUSION; ENZYME SYNTHESIS; GENE MUTATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, AGAR GEL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; GENE EXPRESSION REGULATION, BACTERIAL; METHICILLIN RESISTANCE; MUTATION; POLYMERASE CHAIN REACTION; QUINOLONES; STAPHYLOCOCCUS AUREUS; TRANS-ACTIVATORS;

EID: 51449096075     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Al Sweih N, Mokaddas E, Jamal W, Phillips OA, Rotimi VO. In vitro activity of linezolid and other antibiotics against Gram-positive bacteria from the major teaching hospitals in Kuwait. J Chemother. 2005 Dec; 17(6): 607-13.
2. Bell JM, Turnidge JD. High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY antimicrobial surveillance program, 1998-1999. Antimicrob Agents Chemother. 2002 Mar; 46(3): 879-81.
3. Blondeau JM. Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections. Expert Opin Investig Drugs 2001 Feb; 10: 213-37. Review.
4. Clinical and Laboratory Standards Institute/NCCLS, Performance standards for antimicrobial susceptibility testing; Fifteenth Informational Supplement. 2005 CLSI/NCCLS document M100-S15. Wayne, PA
5. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3): 377-92. Review.
6. Evans ME, Titlow WB. Levofloxacin selects fluoroquinoloneresistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin. J Antimicrob Chemother. 1998 Feb; 41(2): 285-8.
7. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis. 2001 Oct; 1(3): 147-55. Review.
8. Hooper DC. Mechanisms of quinolone resistance. Drug Resist Updat. 1999 Feb; 2(1): 38-55.
9. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis. 2000 Aug; 31 Suppl 2: S24-8. Review.
10. Ito H, Yoshida H, Bogaki-Shonai M, Niga T, Hattori H, Nakamura S. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother. 1994 Sep; 38(9): 2014-23.
11. Levine C, Hiasa H, Marians KJ. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim Biophys Acta. 1998 Oct 1; 1400(1-3): 29-43. Review.
12. Limoncu MH, Ermertcan S, Çetin ÇB, Cosar G, Dinç G. Emergence of phenotypic resistance to ciprofloxacin and levofloxacin in methicillin-resistant and methicillin-sensitive Staphylococcus aureus strains. Int J Antimicrob Agents. 2003 May; 21(5): 420-4.
13. Matynia B, Mlodzinska E, Hryniewicz W. Antimicrobial susceptibility patterns of Staphylococcus aureus in Poland obtained by the National Quality Assurance Programme. Clin Microbiol Infect. 2005 May; 11 (5): 379-85.
14. Ng EY, Trucksis M, Hooper DC. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother. 1996 Aug; 40(8): 1881-8.
15. Noguchi N, Oldhara T, Namiki Y, Kumaki Y, Yamanaka Y, Koyama M, Wakasugi K, Sasatsu M. Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. Int J Antimicrob Agents. 2005 May; 25(5): 374-9.
16. Presterl E, Mueller-Uri P, Grisold A, Georgopoulos A, Graninger W. Ciprofloxacin- and methicillin-resistant Staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid. Eur J Clin Microbiol Infect Dis. 2001 Jul; 20(7): 486-9.
17. Samra Z, Ofer O, Shmuely H. Susceptibility of methicillin-resistant Staphylococcus aureus to vancomycin, teicoplanin, linezolid, pristinamycin and other antibiotics. Isr Med Assoc J. 2005 Mar; 7(3): 148-50.
18. Schmitz FJ, Jones ME, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Fluit A, Verhoef J, Hadding U, Heinz HP, Kohrer K. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother. 1998 May; 42(5): 1249-52.
19. Sierra J, Marco MF, Ruiz J, Jiménez de Anta MT, Vila J. Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus. Clin Microbiol Infect. 2002 Dec; 8(12): 781-90.
20. Wang T, Tanaka M, Sato K. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains. Antimicrob Agents Chemother 1998 Feb; 42(2): 236-40.
21. Wichelhaus TA, Kern S, Schäfer V, Brade V. Rapid detection of epidemic strains of methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 1999 Mar; 37(3): 690-3.
22. Voss A, Doebbeling BN. The worldwide prevalence of methicillin-resistant S. aureus. Int J Antimicrob Agents 1995 Apr; 5(2): 101-6.
23. Yamagishi J, Kojima T, Oyamada Y, Fujimoto K, Hattori H, Nakamura S, Inoue M. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1996 May; 40(5): 1157-63.
24. Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, Hutchinson DK, Barbachyn MR, Brickner S. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother. 1996 Apr; 40(4): 839-45.